日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Vanishing Bile Duct Syndrome Caused by a Treatment Regimen Including Avacopan for Microscopic Polyangiitis

治疗方案中包含阿伐可潘（Avacopan）治疗显微镜下多血管炎引起的胆管消失综合征

期刊:Internal Medicine
影响因子:1.1
doi:10.2169/internalmedicine.5043-24
Hishinuma, Mako; Hasegawa, Midori; Minatoguchi, Shun; Umeda, Ryosuke; Koide, Shigehisa; Hayashi, Hiroki; Yuzawa, Yukio; Minamiguchi, Sachiko; Tsuboi, Naotake
发表日期：2026
文献求助 收藏

Dapagliflozin use in tolvaptan-treated patients with ADPKD: exploring renal outcomes in a retrospective study

在接受托伐普坦治疗的ADPKD患者中使用达格列净：一项回顾性研究探讨其肾脏结局

期刊:Clinical Kidney Journal
影响因子:4.6
doi:10.1093/ckj/sfaf269
Nakajima, Ryunosuke; Minatoguchi, Shun; Umeda, Ryosuke; Koide, Shigehisa; Hasegawa, Midori; Hayashi, Hiroki; Tsuboi, Naotake
发表日期：2025
文献求助 收藏

Investigation of the Impact of Tryptophan-Metabolizing Enzymes and Kynurenic Acid on Antibody-Mediated Glomerulonephritis.

研究色氨酸代谢酶和犬尿酸对抗体介导的肾小球肾炎的影响

期刊:FASEB Journal
影响因子:4.2
doi:10.1096/fj.202501800R
Umeda Ryosuke, Ito Yoshimasa, Minatoguchi Shun, Koide Shigehisa, Takahashi Kazuo, Hayashi Hiroki, Hasegawa Midori, Yuzawa Yukio, Yamamoto Yasuko, Saito Kuniaki, Tsuboi Naotake
代谢
发表日期：2025
文献求助 收藏

Additional renoprotective effect of the SGLT2 inhibitor dapagliflozin in a patient with ADPKD receiving tolvaptan treatment

在接受托伐普坦治疗的ADPKD患者中，SGLT2抑制剂达格列净具有额外的肾脏保护作用

期刊:CEN Case Reports
影响因子:0.7
doi:10.1007/s13730-024-00859-1
Minatoguchi, Shun; Hayashi, Hiroki; Umeda, Ryosuke; Koide, Shigehisa; Hasegawa, Midori; Tsuboi, Naotake
SGLT2
发表日期：2024
文献求助 收藏